BremelanotidePrescription medicine
Bremelanotide acts on melanocortin signalling in the brain. Its clinical context is a particular form of distressing low sexual desire, rather than a general boost to sexual performance.
What is Bremelanotide?
Bremelanotide is a synthetic melanocortin-receptor agonist studied for acquired, generalised hypoactive sexual desire disorder in selected premenopausal women. PT-141 is a research name for the same molecule.
How it works
It acts through central melanocortin signalling rather than primarily through the genital blood-flow pathway targeted by sildenafil.
Effects studied
Sexual desire and related distress
Placebo-controlled development studies assessed questionnaire measures of desire and distress in a defined population. These outcomes do not establish a general sexual-performance effect across all sexes or causes of low desire. 4
Evidence: Placebo-controlled trials in selected premenopausal women
What does the evidence show?
The archive points to placebo-controlled trials in premenopausal women with acquired, generalised hypoactive sexual desire disorder. That population and the measured outcomes matter when interpreting broader marketing claims.
What it targets
Sexual desire and the physical response to arousal overlap, but they are different outcomes. Bremelanotide is a synthetic peptide that activates melanocortin receptors. This differs from the blood-vessel mechanism of medicines such as sildenafil. Even a plausible brain pathway cannot explain every cause of low desire.
Who took part in the studies
The Vyleesi programme studied women whose low desire was persistent and distressing, with eligibility criteria that excluded several other explanations. Desire and distress were measured with questionnaires. A change on those scales should not be translated into a guaranteed change in relationships, sexual frequency or satisfaction. The retained trial reference provides the starting point for that distinction. 4
Bremelanotide and PT-141
PT-141 is a research name for the same molecule. A vial using that name is not automatically equivalent to the prescription formulation in a clinical trial: concentration, delivery, impurities and sterility are separate questions. The name alone does not establish those details.
Side effects and assessment
Nausea, flushing and headache feature in the product information. Blood-pressure effects and changes in skin pigmentation also matter. These effects call for individual medical assessment. The compound is not a casual supplement. The archived US label is a historical reference, not a current European prescribing guide. 3
Safety & status
Nausea, flushing and headache occur in product information. Blood-pressure effects and pigmentation changes also need clinical consideration. 3
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is bremelanotide the same as PT-141?
The molecule is the same, but an online vial or spray is not automatically equivalent to a specified prescription formulation.
Is it a substitute for sildenafil?
They address different biological pathways and clinical questions. Desire and the physical response to arousal are related but distinct.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Bremelanotide: www.sciencedirect.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Bremelanotide: palatin.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Bremelanotide: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Bremelanotide: paper 10.1097/AOG.0000000000003500 Research reference · Retained archive reference; not independently checked for this draft.
Related names & questions
Connections help distinguish compounds and uses; they do not imply equivalent benefits.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.